Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Nov 18;2014(11):CD006105.
doi: 10.1002/14651858.CD006105.pub3.

Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome

Leopoldo O Tso  1 , Michael F Costello, Luiz Eduardo T Albuquerque, Régis B Andriolo, Cristiane R Macedo
Affiliations
Meta-Analysis

Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome

Leopoldo O Tso et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied. Metformin reduces hyperinsulinaemia and suppresses the excessive ovarian production of androgens. As a consequence, it is suggested that metformin could improve assisted reproductive techniques (ART) outcomes, such as ovarian hyperstimulation syndrome (OHSS), pregnancy and live birth rates.

Objectives: To determine the effectiveness and safety of metformin as a co-treatment during IVF or intracytoplasmic sperm injection (ICSI) in achieving pregnancy or live birth in women with PCOS.

Search methods: We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE, LILACS, the metaRegister of Controlled Trials and reference lists of articles (up to 15 October 2014).

Selection criteria: Types of studies: randomised controlled trials (RCTs) comparing metformin treatment with placebo or no treatment in women with PCOS who underwent IVF or ICSI treatment.

Types of participants: women of reproductive age with anovulation due to PCOS with or without co-existing infertility factors.Types of interventions: metformin administered before and during IVF or ICSI treatment.Types of outcome measures: live birth rate, clinical pregnancy rate, miscarriage rate, incidence of ovarian hyperstimulation syndrome , incidence of participant-reported side effects, serum oestradiol level on the day of trigger, serum androgen level, and fasting insulin and glucose levels.

Data collection and analysis: Two review authors independently selected the studies, extracted the data according to the protocol and assessed study quality. The overall quality of the evidence was assessed using GRADE methods.

Main results: We included nine randomised controlled trials involving a total of 816 women with PCOS. When metformin was compared with placebo there was no clear evidence of a difference between the groups in live birth rates (OR 1.39, 95% CI 0.81 to 2.40, five RCTs, 551 women, I(2) = 52%, low-quality evidence). Our findings suggest that for a woman with a 32 % chance of achieving a live birth using placebo or other treatment, the corresponding chance using metformin treatment would be between 28% and 53%.When metformin was compared with placebo or no treatment, clinical pregnancy rates were higher in the metformin group (OR 1.52; 95% CI 1.07 to 2.15; eight RCTs, 775 women, I(2) = 18%, moderate-quality evidence). This suggests that for a woman with a 31% chance of achieving a clinical pregnancy using placebo or no treatment, the corresponding chance using metformin treatment would be between 32% and 49%.The risk of ovarian hyperstimulation syndrome was lower in the metformin group (OR 0.29; 95% CI 0.18 to 0.49, eight RCTs, 798 women, I(2) = 11%, moderate-quality evidence). This suggests that for a woman with a 27% risk of having OHSS without metformin the corresponding chance using metformin treatment would be between 6% and 15%.Side effects (mostly gastrointestinal) were more common in the metformin group (OR 4.49, 95% CI 1.88 to 10.72, for RCTs, 431 women, I(2)=57%, low quality evidence)The overall quality of the evidence was moderate for the outcomes of clinical pregnancy, OHSS and miscarriage, and low for other outcomes. The main limitations in the evidence were imprecision and inconsistency.

Authors' conclusions: This review found no conclusive evidence that metformin treatment before or during ART cycles improved live birth rates in women with PCOS. However, the use of this insulin-sensitising agent increased clinical pregnancy rates and decreased the risk of OHSS.

PubMed Disclaimer

Conflict of interest statement

Review author Dr Michael Costello is a member of the pharmaceutical company Merck Sharp and Dohme (MSD) Australia Elonva Advisory Board Committee. He has received funding to attend ART Scientific Meetings including to present papers not on the review topic. These relationships are declared in the interests of transparency and do not constitute a conflict of interest in this review.

Figures

1
1
Study flow diagram.
2
2
'Risk of bias' graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
3
3
'Risk of bias' summary: review authors' judgements about each methodological quality item for each included study.
4
4
Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.1 Live birth rate per woman.
5
5
Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.2 Clinical pregnancy rate per woman.
6
6
Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.3 Incidence of OHSS per woman.
1.1
1.1
Comparison 1 Metformin versus placebo or no treatment, Outcome 1 Live birth rate per woman.
1.2
1.2
Comparison 1 Metformin versus placebo or no treatment, Outcome 2 Clinical pregnancy rate per woman.
1.3
1.3
Comparison 1 Metformin versus placebo or no treatment, Outcome 3 Incidence of OHSS per woman.
1.4
1.4
Comparison 1 Metformin versus placebo or no treatment, Outcome 4 Miscarriage rate per woman.
1.5
1.5
Comparison 1 Metformin versus placebo or no treatment, Outcome 5 Side effects per woman.
1.6
1.6
Comparison 1 Metformin versus placebo or no treatment, Outcome 6 Number of oocytes retrieved per woman.
1.7
1.7
Comparison 1 Metformin versus placebo or no treatment, Outcome 7 Mean total dose of FSH (IU) per woman.
1.8
1.8
Comparison 1 Metformin versus placebo or no treatment, Outcome 8 Mean days of gonadotrophin per woman.
1.9
1.9
Comparison 1 Metformin versus placebo or no treatment, Outcome 9 Cycle cancellation rate (after ovulation induction).
1.10
1.10
Comparison 1 Metformin versus placebo or no treatment, Outcome 10 Serum oestradiol level (nmol/ l) per woman.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Doldi 2006 {published and unpublished data}
    1. Doldi N, Persico P, Sebastiano F, Marsiglio E, Ferrari A. Gonadotropin‐releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization‐embryo transfer. Gynecological Endocrinology 2006;22(5):235‐8. - PubMed
Fedorcsak 2003 {published data only}
    1. Fedorcsak P, Dale PO, Storeng R, Abyholm T, Tanbo T. The effect of metformin on ovarian stimulation and in vitro fertilization in insulin‐resistant women with polycystic ovary syndrome: an open‐label randomized cross‐over trial. Gynecological Endocrinology 2003;17:207‐14. - PubMed
Kjotrod 2004 {published data only}
    1. Kjotrod S, Düring V, Sunde A, Carlsen SM. Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double‐blind study. Human Reproduction 2003;18 Suppl 1:42‐3. - PubMed
    1. Kjotrod SB, Düring V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction 2004;19(6):1315‐22. - PubMed
    1. Kjøtrød SB, Romundstad P, Düring V, Sunde A, Carlsen SM. Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin‐resistant polycystic ovary syndrome. Fertility and Sterility 2008;89(3):635‐41. - PubMed
Kjotrod 2011 {published data only}
    1. Kjotrod S, Carlsen SM, Rasmussen PE, Holst‐Larsen T, Mellembakken J, Thurin‐Kjellberg A, et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI < 28 kg/m2. Human Reproduction 2010;25(Suppl 1):i286‐7.
    1. Kjotrod SB, Carlsen SM, Rasmussen PE, Holst‐Larsen T, Mellembakken J, Thurin‐Kjellberg A, et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction 2011;26(8):2045‐53. [PUBMED: 21606131] - PubMed
Onalan 2005 {published data only}
    1. Onalan G, Pabuccu R, Goktolga U, Ceyhan T, Bagis T, Cincik M. Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility 2005;84(3):798‐801. - PubMed
Palomba 2011 {published data only}
    1. Palomba S, Falbo A, Carrillo L, Villani MT, Orio F, Russo T, et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin‐stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility 2011;96:1384‐90. - PubMed
Qublan 2009 {published data only}
    1. Qublan HS, Al‐Khaderei S, Abu‐Salem AN, Al‐Zpoon A, Al‐Khateeb M, Al‐Ibrahim N, et al. Metformin in the treatment of clomiphene citrate‐resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology 2009;29(7):651‐5. - PubMed
Tang 2006 {published data only}
    1. Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction 2006;21(6):1416‐25. - PubMed
Visnova 2003 {published data only}
    1. Visnova H, Ventruba P, Crha I, Zakova J. Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie 2003;68(3):155‐62. - PubMed
    1. Visnova H, Ventruba P, Crha I, Zakova J. The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction 2002;17 Suppl:180.

References to studies excluded from this review

Demirol 2006 {published data only}
    1. Demirol A, Sari T, Girgin B, Kent E, Gurgan T. The effect of metformin treatment on the ICSI cycle outcome in PCOS patients. Human Reproduction 2006;21(Suppl 1):i88.
Egbase 2001 {published data only}
    1. Egbase PE, Al Sharhan M, Buzaber M, Grudzinskas JG. Prospective randomised study of metformin in IVF and embryo transfer treatment cycles in obese patients with polycystic ovarian syndrome. Human Reproduction 2001;16 Suppl 1:202.
Geusa 2002 {published data only}
    1. Geusa S, Stanziano A, Causio F, Pansini N, Sarcina E. The efficacy of insulin‐sensitizing agent (metformin) in PCOS and insulin resistance patients undergoing IVF treatment. Human Reproduction 2002;17 Suppl:115.
Kahraman 2001 {published data only}
    1. Kahraman S, Vanlioglu F, Yakin K, Cengiz S, Karlikaya G. A comparative trial of metformin and oral contraceptive pretreatment in patients with polycystic ovary syndrome undergoing ICSI for severe male factor infertility. Fertility and Sterility 2001;76 Suppl 1(3):67.
Palomba 2011b {published data only}
    1. Palomba S, Falbo A, Cello A, Cappiello F, Tolino A, Zullo F. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertility and Sterility 2011;96(5):1128‐33. [PUBMED: 21917254] - PubMed
Schachter 2007 {published data only}
    1. Schachter M, Raziel A, Strassburger D, Rotem C, Ron‐El R, Friedler S. Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin‐resistant polycystic ovary syndrome. Fertility and Sterility 2007;88(1):227‐30. - PubMed
Stadtmauer 1999 {published data only}
    1. Stadtmauer L, Riehl R, Toma S, Talbert L. Use of metformin in patients with PCOS undergoing IVF‐ET improves outcomes. International Journal of Gynecology and Obstetrics 2000;70:p.B41.
    1. Stadtmauer LA, Riehl RM, Toma SK, Huang S, Barker S, Talbert LM. Metformin treatment of patients with polycystic ovarian syndrome undergoing IVF increases the number of mature oocytes, the fertilization rate and the number of embryos with changes in the levels of insulin‐like growth factor. Fertility and Sterility 1999;72 Suppl 1(3):12.
Stadtmauer 2001 {published data only}
    1. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin‐like growth factors. Fertility and Sterility 2001;75(3):505‐9. - PubMed
Stadtmauer 2002 {published data only}
    1. Stadtmauer LA, Wong BC, Oehninger S. Impact of metformin therapy on ovarian stimulation and outcome in 'coasted' patients with polycystic ovary syndrome undergoing in‐vitro fertilization. Reproductive Biomedicine Online 2002;5(2):112‐6. - PubMed
Tasdemir 2004 {published data only}
    1. Tasdemir S, Ficicioglu C, Yalti S, Gurbuz B, Basaran T, Yildirim G. The effect of metformin treatment to ovarian response in cases with PCOS. Archives of Gynecology and Obstetrics 2004;269(2):121‐4. [PUBMED: 12764624] - PubMed

References to studies awaiting assessment

Tang 2010 {published data only}
    1. Tang T, Barth JH, Balen AH. Effect of metformin on follicular anti‐Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction 2010;25(Suppl 1):i68.

Additional references

Aboulghar 2003
    1. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Human Reproduction Update 2003;9:275‐89. - PubMed
Adashi 1985
    1. Adashi EY, Resnick CE, D'Ercole AJ, Svoboda ME, Wyk JJ. Insulin‐like growth factors as intraovarian regulators of granulosa cell growth and function. Endocrine Review 1985;6:400‐20. - PubMed
Attia 2001
    1. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertility and Sterility 2001;76:517‐24. - PubMed
Balen 2004
    1. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Practice & Research. Clinical Obstetrics & Gynaecology 2004;18:685‐6. - PubMed
Barbieri 1986
    1. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 1986;62:904‐10. - PubMed
Barbieri 2000
    1. Barbieri RL. Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. American Journal of Obstetrics and Gynecology 2000;183:1412‐8. - PubMed
Costello 2006
    1. Costello MF, Chapman M, Conway U. A systematic review and meta‐analysis of randomized controlled trials on metformin co‐administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. Human Reproduction 2006;21:1387‐99. - PubMed
Costello 2007
    1. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin‐sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD005552.pub2] - DOI - PubMed
Dunaif 1989
    1. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165‐74. - PubMed
Dunn 1995
    1. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non‐insulin‐dependent diabetes mellitus. Drugs 1995;49:721‐49. - PubMed
ESHRE/ASRM 2003
    1. Rotterdam ESHRE/ASRM ‐ Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004;81:19‐25. - PubMed
Frank 1995
    1. Frank S. Polycystic ovary syndrome. New England Journal of Medicine 1995;333:853‐61. - PubMed
GRADEpro 2011 [Computer program]
    1. GRADE Working Group. GRADE Profiler. Version Version 3.2 for Windows. Brozek J, Oxman A, Schünemann H, 2011.
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Jungheim 2010
    1. Jungheim ES, Odibo AO. Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents. Fertility and Sterility 2010;94(7):2659‐64. - PMC - PubMed
Knochenhauer 1998
    1. Knochenhauer ES, Key TJ, Kahsar‐Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Journal of Clinical Endocrinology and Metabolism 1998;83:3078‐82. - PubMed
Kocak 2002
    1. Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores and pregnancy rates in clomiphene citrate‐resistant women with polycystic ovary syndrome. Fertility and Sterility 2002;77:101‐6. - PubMed
Nardo 2001
    1. Nardo LG, Rai R. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecology and Endocrinology 2001;15:373‐80. - PubMed
Nestler 1991
    1. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone‐binding globulin levels in obese women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1991;72:83‐9. - PubMed
Nestler 2002
    1. Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz DJ. Strategies for the use of insulin‐sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertility and Sterility 2002;77:209‐15. - PubMed
Palomba 2010
    1. Palomba S, Falbo A, Russo T, Orio F, Tolino A, Zullo F. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Human Reproduction 2010;25(4):1005‐13. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Speroff 1995
    1. Speroff L, Glass RH, Kase NG. Anovulation and polycystic ovary [Anovulação e o Ovário Policístico]. Clinical Gynecology, Endocrinology and Infertility. 5th Edition. São Paulo: Manole, 1995:477‐502.
Tang 2012
    1. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD003053.pub5] - DOI - PubMed
Thessaloniki ESHRE/ASRM‐Sponsored PCOS 2008
    1. Thessaloniki ESHRE/ASRM‐Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertility and Sterility 2008;89(3):505‐22. - PubMed
Tsilchorozidou 2004
    1. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clinical Endocrinology 2004;60(1):1‐17. - PubMed
Yarali 2004
    1. Yarali H, Zeyneloglu HB. Gonadotrophin treatment in patients with polycystic ovary syndrome. Reproductive Biomedicine Online 2004;8:528‐37. - PubMed

Publication types